Sanofi and Regeneron said that drug candidate didn’t meet primary endpoint in a phase three study, although a benefit was ...

Shares of Sanofi (NASDAQ:SNY) and its partner Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) are down today after the companies announced that itepekimab met the primary endpoint in only one of the ...

A closely watched biologic drug for chronic obstructive pulmonary disease failed one of two large, late-stage studies, sending shares in its developers, Regeneron Pharmaceuticals and Sanofi, sliding ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Despite challenges, Sanofi is attractively valued ...

Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...

The safety profile of itepekimab was consistent across dosing regimens, and adverse events (AEs) were generally comparable between treatment and placebo groups. Regeneron and Sanofi will review ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in ...

Sanofi and Regeneron said that drug candidate Itepekimab met the primary goal in one of two chronic obstructive pulmonary disease phase 3 studies, but didn’t hit the main objective of a second ...

Anti-drug antibodies were rare and had no apparent impact on itepekimab drug levels. Sanofi and Regeneron are reviewing the data and will discuss with regulatory authorities to evaluate next steps.